US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

27.37

+0.01270.05%

Post-market: 27.500.1304+0.48%16:10 EDT

Volume:1K

Turnover:32.81K

Market Cap:2.46M

PE:- -

High:27.50

Open:27.40

Low:27.37

Close:27.36

52wk High:28.89

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:3.97

T/O Rate:1.33%

Dividend:0.45

Dividend Rate:1.65%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing

BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Press Release: Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

Press Release: Fosun Pharma Announces 2026 Interim Results

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

GlucoTrack subsidiary initiates clinical trial manufacturing for LT-100

Sagimet Biosciences advances AURORA clinical trial

Savara announces presentations of Results from Phase 3 trial of Molgramostim

Syngenis banks R&D refund to fuel biotech build-out

The West Australian

Ribomic Completes Site Network for Phase 3 Achondroplasia Trial in Japan

Moderna’s Shock Rally Redraws the Biotech Playbook

Press Release: 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth

Press Release: Sunshine Guojian Releases 2026 Interim Report:

Regeneron’s Pasatru granted FDA approval for FOP

VOOLT boosts deeptech portfolio with stake in cancer-vaccine biotech Vaxican

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

Arctic Bioscience Sets Date for H1 2026 Results and Investor Webcast

Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray

Memphasys Secures Vietnam Registration for Felix System, Triggers First Major Order

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/NVIB/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":27.3696,"timestamp":1789156800000,"preClose":27.3569,"halted":0,"volume":1193,"hourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.3696,"latestTime":"16:10 EDT","volume":6,"amount":164.2176,"timestamp":1789157404751,"change":0.1304,"changeRate":0.004764,"amplitude":0},"delay":0,"changeRate":0.000464233886149338,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Market Closed","change":0.0127,"latestTime":"09-11 16:00:00 EDT","open":27.401,"high":27.5,"low":27.3696,"amount":32812,"amplitude":0.004767,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":27.3569,"nav":27.319,"aum":2458779,"dividendRate":0.016467,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.3696,"latestTime":"16:10 EDT","volume":6,"amount":164.2176,"timestamp":1789157404751,"change":0.1304,"changeRate":0.004764,"amplitude":0},"volumeRatio":3.974015203722743},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.974015203722743,"shares":90001,"dividePrice":0.4507,"high":27.5,"amplitude":0.004767,"preClose":27.3569,"low":27.3696,"week52Low":24.54,"pbRate":"--","week52High":28.8896,"institutionHeld":0,"latestPrice":27.3696,"eps":0,"divideRate":0.016467,"volume":1193,"delay":0,"ttmEps":0,"open":27.401,"prevYearClose":25,"prevWeekClose":28.8896,"prevMonthClose":27.4504,"prevQuarterClose":25,"fiveDayClose":28.4889,"twentyDayClose":28.3265},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662760410","title":"4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760410","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662760410?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:13","pubTimestamp":1787724830,"startTime":"0","endTime":"0","summary":"4basebio UK Societas ( ($GB:4BB) ) has issued an update. 4basebio PLC, a UK-listed biotech focused on synthetic, cell-free DNA and mRNA for advance...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/4basebio-strikes-genezen-pact-to-advance-synthetic-dna-for-viral-vector-manufacturing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/4basebio-strikes-genezen-pact-to-advance-synthetic-dna-for-viral-vector-manufacturing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VAQC","BK4561","NVIB","BK4121","DNA","XBIX","BK4139","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662530687","title":"BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662530687","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662530687?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:45","pubTimestamp":1787669120,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. FDA has approved the supplemental Biologics License Application for TEVIMBRA in combination with ZIIH...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4526","BK4585","NVIB","MRNX","BMED","BK4139","IBB","TECB","TBXU","MEDI","RSPH","LFSC","PSCH","FRTY","IEIH","PINK","BK4588","GDOC","IYH","XLVX","SYNB","IDNA","MRNY","GNMX","LABU","BBP","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662175807","title":"U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2662175807","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662175807?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:23","pubTimestamp":1787667780,"startTime":"0","endTime":"0","summary":"Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-li","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350636/0/en/u-s-fda-approves-ziihera-zanidatamab-hrii-with-and-without-tislelizumab-plus-chemotherapy-in-first-line-her2-advanced-gastroesophageal-adenocarcinoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBIT","CBTA","CBXO","BITI","HODL","BMED","EZBC","IDNA","BTF","BTCI","GDOC","NVIB","LABU","BRRR","GBTC","BFAP","BITU","CBOJ","BTCW","CBTO","CBTY","BPI","BITB","CBXJ","BTRN","CBXY","YBTC","CRC","CBOY","SBIT","MNRS","BITY","BITO","BTC","BFJL","CBOA","FBTC","DEFI","XBTY","DFII","BTCO","BITX","BCCC","CBTJ","MAXI","BTCC","AEIS","ARKB","BTCL","BTCZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662732058","title":"Press Release: Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662732058","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662732058?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:55","pubTimestamp":1787662500,"startTime":"0","endTime":"0","summary":"President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value ove","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4007","NVIB","LABU","GDOC","DARE","HYLG","03160","BK4585","BK4588","BK4604","MEDX","TM","BK4555","BK4099","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662322847","title":"Press Release: Fosun Pharma Announces 2026 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2662322847","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662322847?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:44","pubTimestamp":1787661840,"startTime":"0","endTime":"0","summary":"Globalization Accelerates Value Realization of Innovative DrugsSHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma (\"the Company\", stock code: 600196.SH; 02196.HK) announced its interim","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK0012","BK0096","BK1593","BK0183","BK4232","BK0188","BK0196","BK4022","NVIB","R","BK1191","BK0175","BK0187","BK0028","BK1515","02196","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662732665","title":"RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662732665","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662732665?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:30","pubTimestamp":1787661000,"startTime":"0","endTime":"0","summary":"PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350436/0/en/renovorx-highlights-peer-reviewed-publication-of-pharmacokinetic-and-pharmacodynamic-pk-pd-data-supporting-tamp-platform-s-targeted-drug-delivery-in-locally-advanced-pancreatic-can.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345780281.USD","LU0274383776.USD","LU1815336091.USD","BK4023","LU2931357623.SGD","IAG","BK4139","IE0031619046.USD","NVIB","IDNA","AEIS","IE00B66KJ199.SGD","BK4585","BK4157","LU0345780521.USD","ODD","IE00B7SZL793.SGD","LU1169589451.USD","MEDX","BK4539","LU2089985449.USD","BK4588","IE00B19Z4B17.USD","GDOC","KBWY","BK4181","RNXT","BK4017","IE0009354923.USD","PK","LU0757428866.USD","LU1169590202.USD","LABU","HYLG","BK4218","BK4183","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662873429","title":"GlucoTrack subsidiary initiates clinical trial manufacturing for LT-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2662873429","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662873429?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:15","pubTimestamp":1787660116,"startTime":"0","endTime":"0","summary":"Lokahi Therapeutics, a subsidiary of Glucotrack (GCTK), announced that it has started its initial Good Manufacturing Practice, GMP, manufacturing c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/glucotrack-subsidiary-initiates-clinical-trial-manufacturing-for-lt-100-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/glucotrack-subsidiary-initiates-clinical-trial-manufacturing-for-lt-100-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","EES","IDNA","MEDX","GCTK","NVIB","BK4082","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773162","title":"Sagimet Biosciences advances AURORA clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773162","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773162?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:40","pubTimestamp":1787658027,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on track to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-advances-aurora-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-advances-aurora-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","GDOC","SGMT","NVIB","BK4139","IDNA","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662206573","title":"Savara  announces presentations of Results from Phase 3 trial of Molgramostim","url":"https://stock-news.laohu8.com/highlight/detail?id=2662206573","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662206573?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:10","pubTimestamp":1787602218,"startTime":"0","endTime":"0","summary":"Savara (SVRA) announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-announces-presentations-of-results-from-phase-3-trial-of-molgramostim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-announces-presentations-of-results-from-phase-3-trial-of-molgramostim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","NVIB","BBC","SVRA","HYLG","BK4139","IDNA","MEDX","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662204407","title":"Syngenis banks R&D refund to fuel biotech build-out","url":"https://stock-news.laohu8.com/highlight/detail?id=2662204407","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662204407?lang=en_us&edition=fundamental","pubTime":"2026-08-24 23:06","pubTimestamp":1787584007,"startTime":"0","endTime":"0","summary":"Biotech hopeful Syngenis Labs has banked a $363,000 R&D tax refund atop a recent $4 million pre-IPO raise, adding non-dilutive firepower as it builds out its Australian RNA and DNA manufacturing platform.","market":"nz","thumbnail":"https://images.thewest.com.au/publication/C-22771960/cfe32dd8d5c27df108386c3ef5f67af0dd0eab91.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22771960/cfe32dd8d5c27df108386c3ef5f67af0dd0eab91.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/syngenis-banks-rd-refund-to-fuel-biotech-build-out-c-22771960","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/syngenis-banks-rd-refund-to-fuel-biotech-build-out-c-22771960","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["GLP","BK4590","NVIB","XBIX","BK4144","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661226379","title":"Ribomic Completes Site Network for Phase 3 Achondroplasia Trial in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2661226379","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661226379?lang=en_us&edition=fundamental","pubTime":"2026-08-24 14:54","pubTimestamp":1787554445,"startTime":"0","endTime":"0","summary":"The latest update is out from Ribomic, Inc. ( ($JP:4591) ). Ribomic has completed the establishment of all planned clinical trial sites for its Pha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ribomic-completes-site-network-for-phase-3-achondroplasia-trial-in-japan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ribomic-completes-site-network-for-phase-3-achondroplasia-trial-in-japan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","IDNA","HYLG","NVIB","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661219445","title":"Moderna’s Shock Rally Redraws the Biotech Playbook","url":"https://stock-news.laohu8.com/highlight/detail?id=2661219445","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661219445?lang=en_us&edition=fundamental","pubTime":"2026-08-22 22:01","pubTimestamp":1787407292,"startTime":"0","endTime":"0","summary":"Moderna ( ($MRNA) ) has risen by 125.15%. Read on to learn why. Moderna has delivered one of the most dramatic moves in biotech this week, with its...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/modernas-shock-rally-redraws-the-biotech-playbook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/modernas-shock-rally-redraws-the-biotech-playbook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","MRNY","BK4532","NVIB","XBIX","BK4568","BK4534","BK4581","BK4501","WDNA","GNOM","BK4139","LGHT","MRNA","BK4585","BK4548","XBI","BK4533","IDNA","MRNX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661250247","title":"Press Release: 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2661250247","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661250247?lang=en_us&edition=fundamental","pubTime":"2026-08-21 15:24","pubTimestamp":1787297040,"startTime":"0","endTime":"0","summary":"SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- 3S Bio (01530.HK) today announced its interim results for the first half of 2026. During the period, the Company recorded revenue of RMB 4.53 billion, represent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","01530","BK1593","BK4232","GDOC","HYLG","R","BK1161","BMED","MEDX","HK0000165453.HKD","NVIB","BK4022","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661258777","title":"Press Release: Sunshine Guojian Releases 2026 Interim Report:","url":"https://stock-news.laohu8.com/highlight/detail?id=2661258777","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661258777?lang=en_us&edition=fundamental","pubTime":"2026-08-21 08:00","pubTimestamp":1787270400,"startTime":"0","endTime":"0","summary":"Innovation-driven, Steady AdvancementSHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Today, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as \"Sunshine Guojian\", stock code: 688","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","NVIB","R","IDNA","BK0239","MEDX","BK1161","HYLG","01530","BK1583","BK1593","BK4232","GDOC","688336","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660287604","title":"Regeneron’s Pasatru granted FDA approval for FOP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660287604","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660287604?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:20","pubTimestamp":1787232025,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration has approved Pasatru to reduce new heterotopic ossification and reduce clinician-assessed disease flare-ups i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","MRNX","MRNY","IBB","MEDI","IYH","TBXU","RSPH","GDOC","LFSC","PSCH","TECB","BBP","BMED","BK4585","GNMX","FRTY","XLVX","LABU","PINK","NVIB","SYNB","IEIH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660845542","title":"VOOLT boosts deeptech portfolio with stake in cancer-vaccine biotech Vaxican","url":"https://stock-news.laohu8.com/highlight/detail?id=2660845542","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660845542?lang=en_us&edition=fundamental","pubTime":"2026-08-20 20:17","pubTimestamp":1787228270,"startTime":"0","endTime":"0","summary":"The latest update is out from VOOLT Spolka Akcyjna ( ($PL:VLT) ). VOOLT S.A. has signed a preliminary agreement to acquire 108 shares in Polish bio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voolt-boosts-deeptech-portfolio-with-stake-in-cancer-vaccine-biotech-vaxican?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voolt-boosts-deeptech-portfolio-with-stake-in-cancer-vaccine-biotech-vaxican?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","VLT","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660288600","title":"BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660288600","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660288600?lang=en_us&edition=fundamental","pubTime":"2026-08-20 17:30","pubTimestamp":1787218200,"startTime":"0","endTime":"0","summary":"Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/20/3348151/0/en/biontech-highlights-late-stage-lung-cancer-pipeline-momentum-and-first-global-data-for-pumitamig-elfetabart-drozuntecan-novel-novel-combination-at-wclc-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","NVIB","GDOC","LU2487616109.SGD","LU0210528500.USD","MEDX","L","IDNA","BK4588","BK4585","LU0053666078.USD","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660835402","title":"Arctic Bioscience Sets Date for H1 2026 Results and Investor Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2660835402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660835402?lang=en_us&edition=fundamental","pubTime":"2026-08-20 16:08","pubTimestamp":1787213283,"startTime":"0","endTime":"0","summary":"An announcement from Arctic Bioscience AS ( ($DE:9TD) ) is now available. Arctic Bioscience AS, a biotech company specializing in pharmaceutical an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arctic-bioscience-sets-date-for-h1-2026-results-and-investor-webcast?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arctic-bioscience-sets-date-for-h1-2026-results-and-investor-webcast?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AS","XBIX","NVIB","BK4202","LNGR","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660028408","title":"Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2660028408","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660028408?lang=en_us&edition=fundamental","pubTime":"2026-08-20 12:43","pubTimestamp":1787200984,"startTime":"0","endTime":"0","summary":"Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) just unveiled an announcement. Glenmark Pharmaceuticals has secured U.S. FDA approval for its F...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","IYH","PSCH","LABU","SYNB","MRNY","BMED","BBP","IBB","PINK","RSPH","MRNX","IDNA","BK4585","IEIH","LFSC","GDOC","FRTY","TBXU","GNMX","XLVX","TECB","NVIB","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660479252","title":"Memphasys Secures Vietnam Registration for Felix System, Triggers First Major Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2660479252","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660479252?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:31","pubTimestamp":1787182297,"startTime":"0","endTime":"0","summary":"Memphasys Ltd ( ($AU:MEM) ) has shared an announcement. Memphasys Ltd, an Australian reproductive biotech specialist, is commercialising its Felix ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/memphasys-secures-vietnam-registration-for-felix-system-triggers-first-major-order?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/memphasys-secures-vietnam-registration-for-felix-system-triggers-first-major-order?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX","MEM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":4,"totalSize":174,"code":"91000000","status":"200"}]}}